Prophylaxis News and Research

RSS

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

11 Aug 2010

FDA approves Pfizer's Prefilled Dual-Chamber Syringe for XYNTHA administration in hemophilia A patients

Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.

9 Aug 2010

ViroPharma announces data on safety, efficacy of Cinryze to treat acute angioedema attacks

ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.

6 Aug 2010

Rush University Medical Center first to receive Octapharma grant under anniversary program

Octapharma USA today announced the first grant recipient of the Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center. The Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

3 Aug 2010

Allergan second-quarter diluted EPS increases to $0.78

Allergan, Inc. today announced operating results for the quarter ended June 30, 2010. Allergan also announced that its Board of Directors has declared a second quarter dividend of $0.05 per share, payable on September 7, 2010 to stockholders of record on August 17, 2010.

3 Aug 2010

ViroPharma second-quarter net sales increase 33% to $109.0 million

ViroPharma Incorporated reported today its financial results for the second quarter ended June 30, 2010.

28 Jul 2010

AIDS 2010: Obama, Clinton vow U.S. support to global fight against HIV/AIDS

During the closing ceremonies of the International AIDS Conference-AIDS 2010, President Barack Obama "on Friday pledged to redouble efforts to fight HIV and AIDS through his Global Health Initiative, despite dealing with economic hard times in the wake of a global recession," Reuters reports. According to the news service, "Obama and his Secretary of State Hillary Clinton said their focus was on a broad, sustainable and effective approach to the global epidemic" (Kelland, 7/23).

26 Jul 2010

AVAC releases GPP Guidelines at International AIDS Conference

The draft second edition of The Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials were released yesterday at the International AIDS Conference in Vienna by AVAC. The GPP Guidelines aim to provide trial funders, sponsors, and implementers with systematic guidance on how to effectively work with a range of stakeholders as they design and conduct biomedical HIV prevention trials.

23 Jul 2010

AIDS 2010 calls for extension of human rights protections as central tenet of global response to AIDS

The appalling lack of access to scientifically proven interventions for key populations at risk -- including sex workers, men who have sex with men and people who use drugs - and the lagging scale up of simple and inexpensive treatment regimens to prevent vertical transmission of HIV reflect persistent, underlying human rights violations that threaten future progress on AIDS, according to organizers of the XVIII International AIDS Conference taking place in Vienna this week under the theme of Rights Here, Right Now.

23 Jul 2010

Drugs can save African infants' lives

Researchers at the University of Sydney have found the combined intake of iron-folic acid supplements with World Health Organisation (WHO)-endorsed anti-malarial drugs during pregnancy could reduce early infant mortality in sub-Saharan Africa by a quarter.

22 Jul 2010

Study marks significant milestone for microbicide research field, HIV prevention

Today we congratulate the Centre for the AIDS Programme of Research in South Africa and the people of South Africa on the positive findings from the CAPRISA 004 microbicide study, which marks a significant milestone both for the microbicide research field and HIV prevention as a whole.

22 Jul 2010

Flat global funding for HIV prevention research could have serious consequences: Report

Following significant advances in vaccine and microbicide research, including results presented today of 39% efficacy in the CAPRISA 004 microbicide gel trial among women in South Africa, a new report released today warns that flat funding for HIV prevention research may limit researchers' ability to quickly move promising approaches forward.

22 Jul 2010

AIDS 2010 studies, releases: PMTCT, treating children, male circumcision; National prevention programs; IDUs

"In parts of Africa, only about half of babies born to mothers with HIV receive the HIV prevention drug nevirapine," according to a study published Wednesday, HealthDay News/U.S. News & World Report reports.

22 Jul 2010

New insights on early pathogenic events, strategies for preventing HIV infection

In a plenary lecture at the 18th International AIDS conference in Vienna, Austria, Anthony S. Fauci, M.D., will present new insights on the early and complex pathogenic events that occur rapidly-within hours to days-following sexual exposure to HIV.

21 Jul 2010

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AiCuris announced today publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246 is a novel anti-HCMV drug currently in clinical phase 2 testing.

21 Jul 2010

Natural, needle-free vaccination against malaria

If mice are administered an antibiotic for three days and are simultaneously infected with malaria, no parasites appear in the blood and life-threatening disease is averted. In addition, the animals treated in this manner also develop robust, long-term immunity against subsequent infections. This discovery was made by the team headed by Dr. Steffen Borrmann from the Department of Infectious Diseases at Heidelberg University Hospital in cooperation with Dr. Kai Matuschewski of the Max Planck Institute for Infection Biology in Berlin. The scientists think that safe and affordable prophylaxis with antibiotics in residents of areas with high malaria transmission has the potential to be used as a natural "needle-free" vaccination against malaria.

21 Jul 2010

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) drug called tenofovir found its use before and after sex was significantly more protective against HIV infection than a placebo gel among women at high risk of HIV. Results of the study, known as CAPRISA 004, are to be reported at the International AIDS Conference (AIDS 2010) in Vienna and published online by the journal Science.

20 Jul 2010

Only 51% of HIV-exposed infants received minimal dose of prevention drug nevirapine: Study

In the ongoing battle to prevent mother-to-child transmission of human immunodeficiency virus (HIV), not all weapons are being used: Only about half of HIV-exposed infants in some African countries received a minimal dose of the prevention drug nevirapine, say researchers at the University of Alabama at Birmingham.

20 Jul 2010

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

"This is a historic day for HIV prevention research. The CAPRISA 004 results are the first clinical evidence that a microbicide gel can help to prevent sexual transmission of HIV infection," said AVAC Executive Director Mitchell Warren, reacting to the results of the landmark microbicide trial presented today at the International AIDS Conference in Vienna.

20 Jul 2010

Researchers identify a substance that protects farm children from allergies, allergic asthma

Researchers from Bochum have isolated the substance in cowshed dust that possibly protects farm children from developing allergies and allergic asthma, namely the plant sugar molecule arabinogalactan. If high concentrations thereof are inhaled during the first year of life it inhibits the immune system from excessive defense reactions.

20 Jul 2010

Prophylaxis News and Research

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

FDA approves Pfizer's Prefilled Dual-Chamber Syringe for XYNTHA administration in hemophilia A patients

ViroPharma announces data on safety, efficacy of Cinryze to treat acute angioedema attacks

Rush University Medical Center first to receive Octapharma grant under anniversary program

Allergan second-quarter diluted EPS increases to $0.78

ViroPharma second-quarter net sales increase 33% to $109.0 million

AIDS 2010: Obama, Clinton vow U.S. support to global fight against HIV/AIDS

AVAC releases GPP Guidelines at International AIDS Conference

AIDS 2010 calls for extension of human rights protections as central tenet of global response to AIDS

Drugs can save African infants' lives

Study marks significant milestone for microbicide research field, HIV prevention

Flat global funding for HIV prevention research could have serious consequences: Report

AIDS 2010 studies, releases: PMTCT, treating children, male circumcision; National prevention programs; IDUs

New insights on early pathogenic events, strategies for preventing HIV infection

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

Natural, needle-free vaccination against malaria

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Only 51% of HIV-exposed infants received minimal dose of prevention drug nevirapine: Study

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

Researchers identify a substance that protects farm children from allergies, allergic asthma

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News